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bjectives The aim of this report was to evaluate 12-month outcomes of facilitated percutaneous
oronary intervention (PCI) in the FINESSE (Facilitated Intervention with Enhanced Reperfusion
peed to Stop Events) trial.
ackground Treatment delays remain common for patients with primary PCI leading to studies
valuating possible beneﬁt of “facilitated” PCI. In the FINESSE trial, no reduction in the 90-day pri-
ary ischemic end point and an increase in bleeding were observed with both facilitated ap-
roaches, although modest favorable trends were seen for some patient subgroups.
ethods A total of 2,452 patients with ST-segment elevation myocardial infarction (MI) and antici-
ated 1 to 4 h delay until catheterization were randomized to reduced-dose reteplase  abciximab,
bciximab alone, or placebo, followed by expedited primary PCI. Placebo-treated patients received
bciximab in the cath lab. One-year mortality was a pre-speciﬁed secondary end point.
esults One-year mortalities in the 3 groups noted in the preceding text were 6.3%, 7.4%, and 7.0%,
espectively (p  NS), representing 1.1%, 1.9%, and 2.5% increments since the 90-day outcome (p 
.053 for combination treatment vs. primary PCI). A favorable trend with combination treatment was
een for patients with anterior MI (p  0.09), but no other speciﬁed groups beneﬁted or tended to ben-
ﬁt. Independent baseline correlates of 1-year mortality were systolic blood pressure 100 mm Hg, prior
I, age, Killip class 1, anterior MI, body mass index 25 kg/m2, heart rate 100 beats/min, and no
tatin use.
onclusions These results suggest that widespread utilization of the facilitated approaches tested
annot be justiﬁed, but that high-risk patient groups such as patients with anterior MI may deserve
urther study. (The FINESSE trial; NCT00046228) (J Am Coll Cardiol Intv 2009;2:909–16) © 2009 by the
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910atient delays during treatment of ST-segment elevation
yocardial infarction (STEMI) with primary percutaneous
oronary intervention (PCI) remain common (1). The
INESSE (Facilitated Intervention with Enhanced Reper-
usion Speed to Stop Events) trial formally evaluated 2
ossible “facilitation” strategies, attempting to safely achieve
eperfusion before PCI (2). In the aggregate of patients
tudied, neither half dose reteplase  abciximab (combina-
ion facilitated PCI), nor abciximab alone given as soon as
ossible proved superior to primary PCI with abciximab in
he catheterization lab in reducing the primary end point
3). Infarct size as estimated by area under the creatine
inase release curve was, however, reduced by combination
herapy (1,625 IU/l /h) compared with both early abciximab
1,782 IU/l/h) and in lab abciximab (1,860 IU/l/h) (p 
.01 and p  0.001, respectively). In addition, modestly
avorable trends with combination therapy in the primary
linical end point were seen for patients randomized 3 h
rom symptom onset and for high-risk patients (any of
nterior myocardial infarction [MI], Killip class 1, heart
ate at presentation 100 beats/min) (3). Conversely, both
acilitation approaches increased bleeding (e.g., nonintra-
cranial Thrombolysis In Myo-
cardial Infarction (TIMI) (major
or minor bleeding 14.5% vs. 6.9%;
p  0.001 combination and pri-
mary PCI, respectively) (3).
One-year mortality was a pre-
specified secondary end point,
whose outcome may well be ex-
pected to reflect the long-term
effects of infarct size modifica-
ion and bleeding (4–6). The present report summarizes the
etween-treatment results at 1 year among all randomized
atients and various pre-specified subgroups.
ethods
atients with ST-segment elevation suggesting acute MI
ith symptoms 6 h, eligible for either fibrinolytic therapy
r primary PCI, and for whom the estimated time to
iagnostic catheterization was 1 to 4 h, were eligible for
andomization. Patients 60 years of age with isolated
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bbreviations
nd Acronyms
I  myocardial infarction
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarctionanuscript received July 7, 2009; accepted July 9, 2009.nferior wall MI were excluded due to their low risk. Further
etails of the study design have been previously reported (2).
his study was approved by the local institutional review
oards, and all patients provided written informed consent.
Patients were randomized in a double-blind double dummy
ashion to receive reteplase  abciximab (combination-
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Table 1. Multivariable Logistic Regression Model: Correlation With
1-Year Mortality
Variable
Hazard
Ratio
Lower
95% CI
Upper
95% CI p Value
Randomized treatments
Combination facilitated PCI
vs. primary PCI
0.82 0.56 1.19 0.293
Abciximab facilitated vs.
primary PCI
0.99 0.68 1.43 0.952
Baseline variables included in
the model
Age (per yr) 1.08 1.06 1.09 0.0001
History of prior MI 2.48 1.68 3.65 0.0001
Systolic BP 100 mm Hg 4.38 2.66 7.21 0.0001
Killip class 1 2.08 1.45 3.00 0.0001
Anterior MI 1.81 1.32 2.50 0.0003
BMI 25 kg/m2 1.57 1.14 2.16 0.006
Pulse rate 100 beats/min 1.99 1.21 3.29 0.007
No statin within 7 days
before randomization
1.95 1.13 3.35 0.016
Thienopyridine within 7 days
before randomization
0.57 0.31 1.04 0.065
Western Europe vs. Eastern
Europe
0.69 0.47 1.03 0.068
NA and ROW vs. Eastern
Europe
0.55 0.27 1.12 0.100
Diabetes 1.32 0.90 1.93 0.155
Aspirin within 7 days before
randomization
1.30 0.90 1.87 0.168
Women 0.84 0.58 1.19 0.325
Hub site 0.87 0.63 1.20 0.387
Prior CHF 1.45 0.57 3.67 0.438
Symptom onset to
randomization 3 h
0.91 0.66 1.25 0.546
Smoker 0.92 0.66 1.29 0.649
LMWH substudy 0.99 0.67 1.48 0.968
BP blood pressure; BMI body mass index; CHF congestive heart failure; CI confidence
interval; LMWH low-molecular-weight heparin; MImyocardial infarction; NANorth Amer-
ica; PCI percutaneous coronary intervention; ROW rest of world.
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911acilitated PCI), abciximab alone (abciximab-facilitated
CI), or placebo as soon as possible, with the latter group
eceiving abciximab in the cath lab while the other patients
eceived placebo. Dosing regimens and adjunctive anti-
hrombin therapy have been previously described (2).
Figure 1. All-Cause Mortality Through 1 Year for Each of the
3 Treatment Groups (Intention to Treat)
Table 2. Baseline Characteristics and Initial Treatment
Primary PCI
(n  806)
Abciximab-Facili
(n  81
Women 207 (25.7) 216 (26.
Age (yrs), mean  SD 62.5 11.4 61.9 11
75 678 (84.1) 695 (85.
75 128 (15.9) 123 (15.
Cigarette smoker
Past or current 524 (65.0) 549 (67.
Current smoker 357 (44.3) 363 (44.
Diabetes 133 (16.5) 119 (14.
Treated with insulin 29 (3.6) 28 (3.4
Previous MI 82 (10.2) 80 (9.8
Previous CHF 13 (1.6) 9 (1.1
Hypertension 374 (46.4) 405 (49.
Hypercholesterolemia 276 (34.2) 249 (30.
Treated 131 (16.3) 125 (15.
Location of infarction
Anterior 370 (45.9) 403 (49.
Inferior/posterior 358 (44.4) 358 (43.
Other 141 (17.5) 117 (14.
Not localized 10 (1.2) 4 (0.5
Killip class
I 713 (88.5) 714 (87.
II 67 (8.3) 81 (9.9
III 11 (1.4) 6 (0.7
IV 2 (0.2) 0 (0.0
Unknown 13 (1.6) 17 (2.1
Data are reported as n (%) unless otherwise noted.
Abbreviations as in Table 1.tated PCI
8)
Reteplase/Abciximab-Facilitated PCI
(n  828) p Value
4) 219 (26.4) 0.925
.8 62.6 11.4
0) 691 (83.5) 0.702
0) 137 (16.5)
1) 537 (64.9) 0.561
4) 347 (41.9) 0.518
5) 128 (15.5) 0.553
) 32 (3.9) 0.890
) 104 (12.6) 0.146
) 12 ( 1.4) 0.664
5) 394 (47.6) 0.448
4) 291 (35.1) 0.510
3) 144 (17.4)
3) 400 (48.3) 0.375
8) 378 (45.7)
3) 110 (13.3)
) 6 (0.7)
0.376
3) 741 (89.5)
) 68 (8.2)
) 3 (0.4)
) 3 (0.4)
) 13 (1.6)PCI  percutaneous coronary intervention.Table 3. Independent Correlates of 1-Year Mortality: Landmark Analysis
From Day 7
Variable
Hazard
Ratio
Lower
95% CI
Upper
95% CI p Value
Randomized treatments
Combination facilitated PCI vs.
primary PCI
0.55 0.33 0.93 0.026
Abciximab facilitated vs. primary PCI 0.89 0.56 1.43 0.633
Post-randomization variables
TIMI major or minor bleed through
day 7
3.18 1.99 5.08 0.0001
Baseline variables
Age (per yr) 1.08 1.05 1.10 0.0001
History of prior MI 3.35 2.06 5.46 0.0001
Anterior MI 2.04 1.34 3.12 0.0001
Killip class 1 2.17 1.33 3.53 0.002
Western Europe vs. Eastern Europe 0.48 0.28 0.82 0.007
Thienopyridine within 7 days before
randomization
0.36 0.14 0.91 0.031
Systolic BP 100 mm Hg 2.54 1.07 5.99 0.034
MImyocardial infarction; PCI percutaneous coronary intervention; TIMI Thrombolysis InMyocardial Infarction; other abbreviations as in Table 1.
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912The primary end point was a composite of death from all
auses, ventricular fibrillation occurring 48 h after ran-
omization, cardiogenic shock or congestive heart failure at
0 days and has been previously reported (3).
Follow-up through 1 year was obtained in 98.6%, 98.3%,
nd 97.6% of the combination-facilitated, abciximab-
Figure 2. Comparison of 1-Year All-Cause Mortality in Subgroups
Comparison of 1-year all-cause mortality in subgroups. (A) Combination treatm
abciximab). Continued on next pageacilitated, and primary PCI groups (p  NS). tSurvival analysis was performed using Cox propor-
ional hazards models to evaluate independent baseline
isk factors. Comparisons of area under creatine kinase
urve to estimate infarct size and subgroup analyses were
erformed as previously described (3). To assess the
ssociation between baseline variables and also outcomes
ersus primary percutaneous coronary intervention (PCI) (with in labent vhrough day 7 post-randomization and 1-year mortality,
l
d
h
a
m
v
t
u
2
S
C
R
S
p
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 0 , 2 0 0 9 Ellis et al.
O C T O B E R 2 0 0 9 : 9 0 9 – 1 6 1-Year Survival in the FINESSE Trial
913andmark analyses (7,8), which included patients alive through
ay 7, were carried out using Cox models with time varying
azards. To investigate which baseline characteristics were
ssociated with 1-year mortality in the study population, a
ultivariate Cox model was used including pre-selected co-
ariates (Table 1). No model selection procedure was under-
aken to control the bias that may be introduced by model
ncertainty. Statistical significance was determined at the
Figure 2. Continued
(B) Abciximab-facilitation versus primary PCI (with in lab abciximab). CI  con
MI  myocardial infarction.-sided value of p  0.05. Analyses were performed with cAS software, version 8.02 (SAS Institute Inc., Cary, North
arolina).
esults
ummary baseline demographics and medical history for the
atients in the 3 treatment groups are provided in Table 2.
edian interval from symptom onset to qualifying electro-
e interval; ECG  electrocardiogram; LMWH  low molecular weight heparin;ﬁdencardiogram was 2.1 (1.2 to 3.3 interquartile) h. Door-to-
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914alloon time was 2.2 (1.8 to 2.8 interquartile) h. There were
o significant differences in any of the baseline parameters
easured. Infarct size estimated by CK curve analyses for
nterior MIs, stratified by treatment group, reteplase 
bciximab, abciximab, primary PCI were 1,684 (p  0.015
s. primary PCI), 1,792 (p  0.247 vs. primary PCI) and
,966 (median value [IU/l/h]). For nonanterior MIs, the
alues were 1,147 (p  0.015 vs. primary PCI), 1,288 (p 
.857 vs. primary PCI), and 1,322 IU/l/h, respectively.
IMI major and minor bleeding was seen in 17.3%, 10.4%,
nd 7.0% of patients in the anterior MI subgroup and
2.2%, 9.6%, and 7.6% in the nonanterior MI subgroups,
espectively, for the 3 treatment groups noted in the
receding text. At hospital discharge or Day 7 (whichever
Figure 3. All-Cause Mortality Through 1 Year for Each of the
3 Treatment Groups
All-cause mortality through 1 year for each of the 3 treatment groups for
(A) anterior MI subgroup and (B) nonanterior MI subgroup. Abbreviations
as in Figure 2.as earlier), 75.0%, 75.9%, 74.2%, and 83.5%, 85.5%, and 04.1% in the combination-facilitated, abciximab-facilitated,
nd primary PCI groups received angiotensin-converting
nzyme inhibitors (or angiotensin II receptor blockers) and
eta-blockers, respectively (all p  NS).
All-cause mortality at 1 year was, 6.3%, 7.4%, and 7.0% in the
ombination- facilitated PCI, abciximab-facilitated PCI, and
rimary PCI with in-lab abciximab groups, respectively (pNS)
Fig. 1), which represented a 1.1%, 1.9%, and 2.5% increment
rom the initial 90-day end point (p 0.053 for combination vs.
rimary PCI). The mortality difference between combination-
acilitated PCI and primary PCI after correction for confounders
n multivariate landmark analysis for survivors at day 7 was
ignificant at p  0.026 (Table 3).
One-year mortalities in pre-specified subgroups, referenced
gainst the primary PCI control, are shown in Figures 2A and 2B.
lthough these results must be interpreted with caution, patients
ith anterior MI (35% relative reduction in mortality [subset p
.093, interaction p  0.065]) appeared possibly to benefit with
ombination-facilitated PCI (Fig. 3).
Independent correlates of 1-year mortality in the entire
tudy cohort are presented in Tables 1 and 3. Table 1 shows
he impact of variables available before randomization, notably
ypotension, prior MI, age, Killip class, and infarct location.
he treatment to which the patient was randomly allocated
reteplase  abciximab combination, abciximab alone, or
lacebo with later in-lab abciximab) was not correlated with
utcome after consideration of other variables. In Table 3
andmark analysis from day 7 shows correlates of mortality
rom that point onward, the risk associated with TIMI major
r minor bleeding and covariates from the baseline analysis, as
ell as the benefit of combination reteplase and abciximab on
ortality from that time forward. Figure 4 shows the impact
n 1-year mortality of TIMI major or minor bleeding in the
andmark analysis from day 7 for all treatment groups and by
ach treatment group separately.
iscussion
he competing treatment outcomes of infarct size reduction
nd major bleeding have been shown to strongly influence
ong-term survival in patients treated with STEMI (4–6).
n the 2,452 patient FINESSE trial, combination facilita-
ion therapy with half-dose reteplase  abciximab was
hown to significantly reduce infarct size but also increase
ajor bleeding compared with primary PCI and in-lab
bciximab at 7 days, but to have no overall clinical benefit at
he time of the primary study end point at 90 days (3). The
rincipal findings of this 12-month outcome analysis are: of
re-specified secondary end points: 1) there was no differ-
nce among the 3 treatment groups in overall mortality;
) the anterior MI subgroup exhibited a strong trend toward
mproved survival with combination facilitated PCI com-
ared with primary PCI with abciximab in the lab (p 
.093); and in post hoc analyses; 3) advanced age, prior MI,
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915IMI major or minor bleeding through day 7, anterior MI,
illip class 1 at presentation, body mass index 25 kg/m2,
eart rate 100 beats/min, and Eastern (vs. Western) Euro-
ean origin were the strongest correlates of 12-month mortal-
ty; and 4) combination facilitated PCI significantly reduced
2-month mortality compared with primary PCI in a
andmark analysis from day 7 (p  0.026).
The majority of independent correlates of 1-year mortality
systolic blood pressure, prior MI, age, MI location, and Killip
lass) have been previously described (9,10). In the baseline
odel, after adjusting for these factors, neither facilitated
reatment was associated with a survival benefit at 1 year.
mportantly, TIMI bleeding was a strong independent corre-
ate of risk (hazard ratio: 3.18, p 0.0001). Nevertheless, even
ith that considered in the model, treatment with half-dose
eteplase  abciximab was correlated with improved survival
hazard ratio: 0.55, p 0.026), suggesting that if there was no
xcess bleeding with combination therapy it would have
Figure 4. Landmark Analysis From Day 7 Through 1 Year
Landmark analysis from day 7 through 1 year showing impact of Thrombolysis
overall and in each of the 3 treatment groups: (A) all treatment groups; (B) pr
coronary intervention; and (D) combination facilitated percutaneous coronarymproved 1-year survival. Clearly, bleeding cannot be elimi- wated, but these and the landmark findings suggest a clear early
azard, late benefit, and influence with reteplase abciximab.
Although subgroup analysis must be performed with
onsiderable caution in a study whose overall treatment
enefit was not statistically different compared with the
ontrol group and in which multiple subgroups of pa-
ients were pre-specified for subsequent examination, the
rend toward a reduction in 1-year mortality in the
nterior MI group treated with combination therapy is
ntriguing. These patients had larger infarcts but no
xcess in bleeding risk compared with patients with other
ypes of infarcts, and hence potentially the most to gain
rom early reperfusion therapy. These data complement
he previously reported trends toward benefit in the
rimary composite end point at 90 days in early treated
nd high-risk individuals (3), and hence suggest the
atient substrate most requiring further study of similar
arly reperfusion strategies to be utilized in conjunction
yocardial Infarction (TIMI) major or minor bleeding on subsequent mortality
percutaneous coronary intervention; (C) abciximab-facilitated percutaneous
ntion.In M
imaryith primary PCI.
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916In considering these results, several limitations should
e kept in mind. Principally, these include the fact that
ultiple post hoc secondary analyses are considered
ithout Bonferroni or other adjustment (both 12-month
ortality and the anterior MI subgroup analyses were
re-specified, however) and that the study was not
owered for such comparisons (even the primary end
oint was somewhat underpowered due to early ter-
ination of the study). Hence, findings are intended to
e hypothesis-generating. Finally, the project had
ollow-up scheduled only through 12 months. Conclu-
ions regarding outcomes of high-risk or other subgroups
e.g., anterior MI) might change with longer time of
ollow-up.
onclusions
n summary, 1-year follow-up survival data in the FI-
ESSE trial confirms the overall lack of significant clinical
enefit with either of the treatment regimens tested, al-
hough at the same time suggesting further study may be
eeded in certain high-risk groups and the need to find
herapies that improve reperfusion without greatly increas-
ng bleeding risk.
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